Jun 08, 2021 / 12:00PM GMT
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Aclaris Therapeutics Presents ATI-1777 Clinical Update. (Operator Instructions)
I would now like to hand the conference over to your speaker today, Ms. Kamil Ali-Jackson.
Kamil Ali-Jackson - Aclaris Therapeutics, Inc. - Co-Founder, Chief Legal Officer, Chief Compliance Officer & Corporate Secretary
Thank you, Angie. I am Kamil Ali-Jackson, Chief Legal Officer for Aclaris. Please note that earlier today, Aclaris issued its press release announcing positive preliminary top line results from its Phase IIa clinical trial to determine the efficacy, safety, tolerability and pharmacokinetics of ATI-1777, our investigation topicals soft JAK1/3 inhibitor in subjects with moderate to severe atopic dermatitis. For those of you who have not yet seen it, you will find the release posted under the press releases page of the Investors section of our website at www.aclaristx.com.
Joining me today for the
Aclaris Therapeutics Inc ATI-1777 Clinical Data Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot